KENNEWICK, WA / ACCESSWIRE / July 19, 2016 / Advanced Medical Isotope Corporation (or "AMI") (ADMD), a late stage radiation oncology focused medical device company today provided an update on its intellectual property including trademark expansion in international markets.
AMI continues to aggressively pursue trademark and patent protection for its brachytherapy products in anticipation of international product introduction. The Company has trademarked its leading cancer treatment under the RadioGel(TM) device trademark across the globe. The mark recently received registration in Hong Kong and Singapore. The mark has been allowed in the United States, and is registered under WIPO (World International Property Organization) in Australia, Japan, New Zealand, the Republic of Korea and the European Community (28 countries). It is also registered in the non-WIPO countries of Malaysia, Taiwan and Thailand and is pending in China and Indonesia. The RadioGel(TM) device trademark registration includes multiple product classes in many of these countries.
AMI has a robust patent portfolio that includes exclusive rights under patents that cover medical isotope applications, processing and manufacturing. AMI is currently in negotiations with two organizations to enhance its patent portfolio related to its brachytherapy products.
AMI Founder, CEO and Chairman James C. Katzaroff stated, "As we make forward progress in our product development and commercialization efforts we continue to lay the groundwork for expansion into international markets by protecting our intellectual property in key global markets as well as in the United States. We are pleased with the strong patent and trademark protection established so far and we and will continue to pursue strong international protection of our intellectual property."
About Advanced Medical Isotope Corporation
Advanced Medical Isotope Corporation (ADMD) is a late stage radiation oncology focused medical device company engaged in the development of yttrium-90 based brachytherapy devices for the treatment of non resectable tumors. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area. The Company intends to outsource material aspects of manufacturing, distribution, sales and marketing for its products in the United States and to enter into licensing arrangements outside of the United States, though the Company will evaluate its alternatives before finalizing its plans. For more information, please visit our website, www.isotopeworld.com.
Safe Harbor Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.
Advanced Medical Isotope Corporation
James C. Katzaroff, CEO
1021 N Kellogg
Kennewick WA 99336
Circadian Group, IR
Tyler Troup, B. Comm